These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 26101239)

  • 21. Benefit of adjuvant chemotherapy with or without trastuzumab in pT1ab node-negative human epidermal growth factor receptor 2-positive breast carcinomas: results of a national multi-institutional study.
    de Nonneville A; Gonçalves A; Zemmour C; Classe JM; Cohen M; Lambaudie E; Reyal F; Scherer C; Muracciole X; Colombo PE; Giard S; Rouzier R; Villet R; Chopin N; Darai E; Garbay JR; Gimbergues P; Sabiani L; Coutant C; Sabatier R; Bertucci F; Boher JM; Houvenaeghel G
    Breast Cancer Res Treat; 2017 Apr; 162(2):307-316. PubMed ID: 28155054
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association between the HER2 Ile655Val polymorphism and response to trastuzumab in women with operable primary breast cancer.
    Han X; Diao L; Xu Y; Xue W; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
    Ann Oncol; 2014 Jun; 25(6):1158-64. PubMed ID: 24608202
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.
    Tolaney SM; Guo H; Pernas S; Barry WT; Dillon DA; Ritterhouse L; Schneider BP; Shen F; Fuhrman K; Baltay M; Dang CT; Yardley DA; Moy B; Marcom PK; Albain KS; Rugo HS; Ellis MJ; Shapira I; Wolff AC; Carey LA; Overmoyer B; Partridge AH; Hudis CA; Krop IE; Burstein HJ; Winer EP
    J Clin Oncol; 2019 Aug; 37(22):1868-1875. PubMed ID: 30939096
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long term survival of HER2-positive early breast cancer treated with trastuzumab-based adjuvant regimen: a large cohort study from clinical practice.
    Bonifazi M; Franchi M; Rossi M; Zambelli A; Moja L; Zambon A; Corrao G; La Vecchia C; Zocchetti C; Negri E
    Breast; 2014 Oct; 23(5):573-8. PubMed ID: 24934637
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial.
    Untch M; Gelber RD; Jackisch C; Procter M; Baselga J; Bell R; Cameron D; Bari M; Smith I; Leyland-Jones B; de Azambuja E; Wermuth P; Khasanov R; Feng-Yi F; Constantin C; Mayordomo JI; Su CH; Yu SY; Lluch A; Senkus-Konefka E; Price C; Haslbauer F; Suarez Sahui T; Srimuninnimit V; Colleoni M; Coates AS; Piccart-Gebhart MJ; Goldhirsch A;
    Ann Oncol; 2008 Jun; 19(6):1090-6. PubMed ID: 18296421
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Trastuzumab for patients with HER2 positive breast cancer: delivery, duration and combination therapies.
    Pinto AC; Ades F; de Azambuja E; Piccart-Gebhart M
    Breast; 2013 Aug; 22 Suppl 2():S152-5. PubMed ID: 24074778
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Coping with uncertainty: T1a,bN0M0 HER2-positive breast cancer, do we have a treatment threshold?
    Kelly CM; Pritchard KI; Trudeau M; Andreopoulou E; Hess K; Pusztai L
    Ann Oncol; 2011 Nov; 22(11):2387-2393. PubMed ID: 21406473
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adjuvant Chemotherapy and Trastuzumab Is Safe and Effective in Older Women With Small, Node-Negative, HER2-Positive Early-Stage Breast Cancer.
    Cadoo KA; Morris PG; Cowell EP; Patil S; Hudis CA; McArthur HL
    Clin Breast Cancer; 2016 Dec; 16(6):487-493. PubMed ID: 27622751
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nine-Week Versus One-Year Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 10-Year Update of the ShortHER Phase III Randomized Trial.
    Conte P; Bisagni G; Piacentini F; Sarti S; Minichillo S; Anselmi E; Aieta M; Gebbia V; Schirone A; Musolino A; Garrone O; Beano A; Rimanti A; Giotta F; Turletti A; Miglietta F; Dieci MV; Vicini R; Balduzzi S; D'Amico R; Guarneri V
    J Clin Oncol; 2023 Nov; 41(32):4976-4981. PubMed ID: 37748109
    [No Abstract]   [Full Text] [Related]  

  • 30. Adjuvant trastuzumab therapy for HER2-positive breast cancer.
    Jahanzeb M
    Clin Breast Cancer; 2008 Aug; 8(4):324-33. PubMed ID: 18757259
    [TBL] [Abstract][Full Text] [Related]  

  • 31. For or against adjuvant trastuzumab for pT1a-bN0M0 breast cancer patients with HER2-positive tumors: a meta-analysis of published literatures.
    Zhou Q; Yin W; Du Y; Lu J
    PLoS One; 2014; 9(1):e83646. PubMed ID: 24392090
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Regional Nodal Irradiation After Breast Conserving Surgery for Early HER2-Positive Breast Cancer: Results of a Subanalysis From the ALTTO Trial.
    Gingras I; Holmes E; De Azambuja E; Nguyen DH; Izquierdo M; Anne Zujewski J; Inbar M; Naume B; Tomasello G; Gralow JR; Wolff AC; Harris L; Gnant M; Moreno-Aspitia A; Piccart MJ; Azim HA
    J Natl Cancer Inst; 2017 Aug; 109(8):. PubMed ID: 28376188
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of extended aromatase inhibitors for hormone-receptor-positive breast cancer: A literature-based meta-analysis of randomized trials.
    Corona SP; Roviello G; Strina C; Milani M; Madaro S; Zanoni D; Allevi G; Aguggini S; Cappelletti MR; Francaviglia M; Azzini C; Cocconi A; Sirico M; Bortul M; Zanconati F; Giudici F; Rosellini P; Meani F; Pagani O; Generali D
    Breast; 2019 Aug; 46():19-24. PubMed ID: 31051411
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Measurement of Domain-Specific HER2 (ERBB2) Expression May Classify Benefit From Trastuzumab in Breast Cancer.
    Carvajal-Hausdorf DE; Schalper KA; Pusztai L; Psyrri A; Kalogeras KT; Kotoula V; Fountzilas G; Rimm DL
    J Natl Cancer Inst; 2015 Aug; 107(8):. PubMed ID: 25991002
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40--GeparQuattro).
    von Minckwitz G; Rezai M; Fasching PA; Huober J; Tesch H; Bauerfeind I; Hilfrich J; Eidtmann H; Gerber B; Hanusch C; Blohmer JU; Costa SD; Jackisch C; Paepke S; Schneeweiss A; Kümmel S; Denkert C; Mehta K; Loibl S; Untch M
    Ann Oncol; 2014 Jan; 25(1):81-9. PubMed ID: 24273046
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The adjuvant treatment of HER2-positive breast cancer.
    Jelovac D; Wolff AC
    Curr Treat Options Oncol; 2012 Jun; 13(2):230-9. PubMed ID: 22410709
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of early breast cancer patient cohorts who may benefit from lapatinib therapy.
    Strasser-Weippl K; Horick N; Smith IE; O'Shaughnessy J; Ejlertsen B; Boyle F; Buzdar AU; Fumoleau P; Gradishar W; Martin M; Moy B; Piccart-Gebhart M; Pritchard KI; Lindquist D; Rappold E; Finkelstein DM; Goss PE
    Eur J Cancer; 2016 Mar; 56():85-92. PubMed ID: 26829011
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adjuvant trastuzumab reduces locoregional recurrence in women who receive breast-conservation therapy for lymph node-negative, human epidermal growth factor receptor 2-positive breast cancer.
    Kiess AP; McArthur HL; Mahoney K; Patil S; Morris PG; Ho A; Hudis CA; McCormick B
    Cancer; 2012 Apr; 118(8):1982-8. PubMed ID: 21887681
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Small HER2-Positive Breast Cancer: Should Size Affect Adjuvant Treatment?
    Tognela A; Beith J; Kiely B; Bastick P; Lynch J; Descallar J; Mok K
    Clin Breast Cancer; 2015 Aug; 15(4):277-84. PubMed ID: 25676930
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of adjuvant trastuzumab in women with HER2-positive T1a or bN0M0 breast cancer: a population-based cohort study.
    Ali S; Hendry J; Le D; Mondal PK; Sami A; Chalchal H; Haider K; Ahmed O; El-Gayed A; Wright P; Pauls M; Johnson K; Ahmed S
    Sci Rep; 2022 Jan; 12(1):1068. PubMed ID: 35058536
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.